Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 84

1.

A tissue-based draft map of the murine MHC class I immunopeptidome.

Schuster H, Shao W, Weiss T, Pedrioli PGA, Roth P, Weller M, Campbell DS, Deutsch EW, Moritz RL, Planz O, Rammensee HG, Aebersold R, Caron E.

Sci Data. 2018 Aug 7;5:180157. doi: 10.1038/sdata.2018.157.

2.

The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.

Schräder T, Dudek SE, Schreiber A, Ehrhardt C, Planz O, Ludwig S.

Antiviral Res. 2018 Sep;157:80-92. doi: 10.1016/j.antiviral.2018.07.006. Epub 2018 Jul 7.

3.

Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound.

Bruchhagen C, Jarick M, Mewis C, Hertlein T, Niemann S, Ohlsen K, Peters G, Planz O, Ludwig S, Ehrhardt C.

Sci Rep. 2018 Jun 14;8(1):9114. doi: 10.1038/s41598-018-27445-7.

4.

Targeting intracellular signaling as an antiviral strategy: aerosolized LASAG for the treatment of influenza in hospitalized patients.

Scheuch G, Canisius S, Nocker K, Hofmann T, Naumann R, Pleschka S, Ludwig S, Welte T, Planz O.

Emerg Microbes Infect. 2018 Mar 7;7(1):21. doi: 10.1038/s41426-018-0023-3.

5.

Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug.

Droebner K, Haasbach E, Dudek SE, Scheuch G, Nocker K, Canisius S, Ehrhardt C, von Degenfeld G, Ludwig S, Planz O.

Front Microbiol. 2017 Nov 2;8:2130. doi: 10.3389/fmicb.2017.02130. eCollection 2017.

6.

Phenol-Soluble Modulin Peptides Contribute to Influenza A Virus-Associated Staphylococcus aureus Pneumonia.

Bloes DA, Haasbach E, Hartmayer C, Hertlein T, Klingel K, Kretschmer D, Planz O, Peschel A.

Infect Immun. 2017 Nov 17;85(12). pii: e00620-17. doi: 10.1128/IAI.00620-17. Print 2017 Dec.

7.

The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo.

Haasbach E, Müller C, Ehrhardt C, Schreiber A, Pleschka S, Ludwig S, Planz O.

Antiviral Res. 2017 Jun;142:178-184. doi: 10.1016/j.antiviral.2017.03.024. Epub 2017 Apr 2.

8.

Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.

Barth SM, Schreitmüller CM, Proehl F, Oehl K, Lumpp LM, Kowalewski DJ, Di Marco M, Sturm T, Backert L, Schuster H, Stevanović S, Rammensee HG, Planz O.

PLoS One. 2016 Nov 28;11(11):e0167017. doi: 10.1371/journal.pone.0167017. eCollection 2016.

9.

Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.

Muhammad S, Planz O, Schwaninger M.

Cerebrovasc Dis Extra. 2016;6(2):50-9. doi: 10.1159/000447750. Epub 2016 Aug 25.

10.

Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious disease.

Herrmann VL, Hartmayer C, Planz O, Groettrup M.

J Control Release. 2015 Oct 28;216:121-31. doi: 10.1016/j.jconrel.2015.08.019. Epub 2015 Aug 12.

PMID:
26276509
11.

Antiviral activity of Ladania067, an extract from wild black currant leaves against influenza A virus in vitro and in vivo.

Haasbach E, Hartmayer C, Hettler A, Sarnecka A, Wulle U, Ehrhardt C, Ludwig S, Planz O.

Front Microbiol. 2014 Apr 22;5:171. doi: 10.3389/fmicb.2014.00171. eCollection 2014.

12.

The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.

Haasbach E, Reiling SJ, Ehrhardt C, Droebner K, Rückle A, Hrincius ER, Leban J, Strobl S, Vitt D, Ludwig S, Planz O.

Antiviral Res. 2013 Sep;99(3):336-44. doi: 10.1016/j.antiviral.2013.06.008. Epub 2013 Jun 28.

PMID:
23811282
13.

A plant extract of Ribes nigrum folium possesses anti-influenza virus activity in vitro and in vivo by preventing virus entry to host cells.

Ehrhardt C, Dudek SE, Holzberg M, Urban S, Hrincius ER, Haasbach E, Seyer R, Lapuse J, Planz O, Ludwig S.

PLoS One. 2013 May 23;8(5):e63657. doi: 10.1371/journal.pone.0063657. Print 2013.

14.

Development of cellular signaling pathway inhibitors as new antivirals against influenza.

Planz O.

Antiviral Res. 2013 Jun;98(3):457-68. doi: 10.1016/j.antiviral.2013.04.008. Epub 2013 Apr 16. Review.

PMID:
23603495
15.

Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro.

Haasbach E, Hartmayer C, Planz O.

Antiviral Res. 2013 May;98(2):319-24. doi: 10.1016/j.antiviral.2013.03.006. Epub 2013 Mar 20.

PMID:
23523553
16.

The NF-κB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance.

Ehrhardt C, Rückle A, Hrincius ER, Haasbach E, Anhlan D, Ahmann K, Banning C, Reiling SJ, Kühn J, Strobl S, Vitt D, Leban J, Planz O, Ludwig S.

Cell Microbiol. 2013 Jul;15(7):1198-211. doi: 10.1111/cmi.12108. Epub 2013 Feb 5.

PMID:
23320394
17.

PAR1 contributes to influenza A virus pathogenicity in mice.

Khoufache K, Berri F, Nacken W, Vogel AB, Delenne M, Camerer E, Coughlin SR, Carmeliet P, Lina B, Rimmelzwaan GF, Planz O, Ludwig S, Riteau B.

J Clin Invest. 2013 Jan;123(1):206-14. doi: 10.1172/JCI61667. Epub 2012 Dec 3.

18.

The NS1 protein of influenza A virus blocks RIG-I-mediated activation of the noncanonical NF-κB pathway and p52/RelB-dependent gene expression in lung epithelial cells.

Rückle A, Haasbach E, Julkunen I, Planz O, Ehrhardt C, Ludwig S.

J Virol. 2012 Sep;86(18):10211-7. doi: 10.1128/JVI.00323-12. Epub 2012 Jul 11.

19.

The adaptor protein FHL2 enhances the cellular innate immune response to influenza A virus infection.

Nordhoff C, Hillesheim A, Walter BM, Haasbach E, Planz O, Ehrhardt C, Ludwig S, Wixler V.

Cell Microbiol. 2012 Jul;14(7):1135-47. doi: 10.1111/j.1462-5822.2012.01787.x. Epub 2012 Apr 12.

PMID:
22417706
20.

Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo.

Droebner K, Pleschka S, Ludwig S, Planz O.

Antiviral Res. 2011 Nov;92(2):195-203. doi: 10.1016/j.antiviral.2011.08.002. Epub 2011 Aug 11.

PMID:
21854809

Supplemental Content

Loading ...
Support Center